OncoMatch/Clinical Trials/NCT06629597
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Is NCT06629597 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including YL201 and Docetaxel for nasopharyngeal carcinoma.
Treatment: YL201 · Docetaxel · Capecitabine · Gemcitabine — This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CD276 expression testing required (testing required; no eligibility threshold specified)
Subjects are willing to provide the archived or freshly obtained tumor tissue (freshly obtained or archived) for detection of B7-H3 expression
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: PD-(L)1 inhibitor
Have failed prior treatment with PD-(L)1 inhibitors
Must have received: chemotherapy
at least two lines of chemotherapy
Cannot have received: B7-H3-targeted therapy
Previously received B7-H3-targeted drug therapy, including antibody, antibody-drug conjugate (ADC), and chimeric antigen receptor T cell (CAR-T)
Cannot have received: topoisomerase I inhibitor
Prior treatment with a topoisomerase I inhibitor or an antibody-drug conjugate containing a topoisomerase I inhibitor
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify